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For patients with COVID-19, there is a moral obligation to provide good supportive care to prevent
avoidable suffering. This article provides a succinct informative overview, clinical guidance and
information sheets for both patients and families. https://bit.ly/2UPFsOj
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Introduction
Globally, the number of people affected by coronavirus disease 2019 (COVID-19) is rapidly increasing. In
most (>80%), the illness is relatively mild and can be self-managed out of hospital. However, for about
20%, the illness causes respiratory compromise severe enough to require hospital admission [1]. Patients
with severe and critical disease need full active treatment. This may include oxygen for hypoxaemia and
ventilatory support, along with optimal management of complications, e.g. super-imposed bacterial
infection, and any underlying comorbidities, e.g. COPD or congestive heart failure. To date, no antiviral
agent has shown to be effective in treating the disease [2].
Patients with severe disease not considered suitable for escalation to intensive care, i.e. those who are frail
or have multiple comorbidities, are at very high risk of dying, with an estimated death rate of 15–22% [3,
4]. We have a moral obligation to provide good symptom control to prevent avoidable suffering. Thus,
comprehensive care of the patient with COVID-19 requires identification of patients at increased risk of
dying, who would benefit from a parallel approach to management. This encompasses optimal symptom
management for those with severe disease but who will survive, and expert symptom management and
end of life care for those that are deteriorating and in their last days or hours of life. The aim of this
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editorial is to provide a succinct informative overview to guide respiratory healthcare professionals on the
frontline.
Symptom relief
The most common symptoms are breathlessness, cough and fever.
Breathlessness
Breathlessness affects between 5% and 65% of patients with COVID-19 [5–9].
The highest incidence will be in those with severe disease and is expected in those actively dying. The
primary driver of breathlessness is the viral lung infection causing an interstitial pneumonia with a
reduction in lung diffusing capacity; in some patients this evolves to acute respiratory distress syndrome
(ARDS). The experience of breathlessness is also influenced by emotional, environmental, cultural and
social factors, and optimal management requires a holistic approach. These include non-pharmacological
and pharmacological approaches. Non-pharmacological approaches include breathing techniques [10].
Although an electric hand-held fan directed at the face is helpful in other settings [10, 11], this is not
recommended in COVID-19 because of the theoretical infection control risk of spreading infected droplets.
As an alternative, use of facial cooling with wet wipes (binning after each use, as for tissues) can be tried.
Pharmacological approaches are the mainstay of management for patients with severe disease who are
likely to have rapidly worsening breathlessness at rest. Morphine is the opioid of choice [12, 13]. However,
alternative strong opioids can be used. Short-acting oral opioids, given as required, may suffice when
breathlessness is mild. However, in severe disease or at the end of life, continuous infusions of parenteral
opioids are preferable, maximising symptom management, whilst reducing nurse and community staff
time, use of resource-limited protective equipment and exposure. Use of the parenteral route is also
preferred for speed of onset of action and ability to rapidly titrate doses. If there is distressing
breathlessness at rest, opioids should be combined with an anxiolytic sedative, e.g. midazolam (table 1).
Rapid titration of benzodiazepines may be needed. The primary role of oxygen is to correct hypoxaemia.
There is a suggestion it may help breathlessness in severe hypoxaemia [14], but not when mild or absent
[15]. In a comatose/unresponsive dying patient, oxygen can be titrated down with goal of discontinuation,
while concurrently managing symptoms of breathlessness [16].
Cough
Cough affects between 70% and 80% of patients with COVID-19 [5–9].
Potential mechanisms in viral respiratory infection and ARDS include inflammation, epithelial damage,
mucus impaction and neuro-modulatory changes (heightened cough reflex sensitivity) [17]. Evidence for
effective management of acute cough is limited [18, 19]. Adequate hydration and regular small sips of
water may help [20]. However, because of the likely concurrent need for breathlessness management,
strong opioids are likely to be more pragmatic in practice. High-level evidence is limited [21, 22], but
relatively low doses of long-acting oral morphine (5–10 mg twice daily) are helpful in refractory chronic
cough (table 1) [21]. Although these patients do not have chronic cough, opioids may be helpful in
reducing cough alongside treatment for breathlessness [22].
Delirium
Delirium is common in medical illness and almost universal in the last days or hours of life.
Non-pharmacological management includes regular orientation, avoiding constipation, treating pain,
maintaining oxygenation and avoiding urinary retention [23]. When ineffective and where the delirium is
causing significant distress, pharmacological therapy with an antipsychotic (such as haloperidol) should be
considered; in the context of severe breathlessness and at the end of life, a sedative anxiolytic such as
levomepromazine or midazolam should be used (table 1) to allow rapid titration if needed.
Anxiety
Anxiety secondary to breathlessness, social isolation and fear is likely to be present to some degree in all
patients with COVID-19. Severely ill patients may be particularly distressed, due to the looming possibility
that their situation may rapidly worsen and that they may die, potentially compounded by the loss of support
from their families, who are not allowed to visit, and receiving care from health professionals in personal
protective equipment. Non-pharmacological methods such as relaxation therapy and breathing exercises are
effective in mild anxiety but if patients are significantly anxious or have severe disease, the focus should be on
pharmacological management. For severe disease and if people are actively dying, benzodiazepines are likely
to be most effective [24]. Optimal relief may necessitate increasing depths of sedation rapidly in the last days
and hours of life, particularly when associated with severe breathlessness (table 1).
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TABLE 1 Example clinical guidelines for the management of the severe/dying coronavirus disease 2019 (COVID-19) patient
Symptom/need Clinical indication Recommendation
Distressing
breathlessness at rest
• Stat dose morphine 2.5 mg SC/IV + midazolam 2.5 mg SC/IV (reduce both to 1.25 mg if
eGFR <30 or elderly)
If continuous infusion is available
• Morphine 10 mg + midazolam 10 mg CSCI/IV over 24 h OR morphine 5 mg +
midazolam 5 mg CSCI/IV over 24 h (if eGFR <30 or in the elderly)
• In addition, prescribe morphine 2.5 mg + midazolam 2.5 mg SC/IV p.r.n. 4 hourly
(1.25 mg for both if eGFR <30 or in the elderly)
If continuous infusion is not available
• Morphine 2.5 mg SC/IV + midazolam 2.5 mg SC/IV 4 hourly (1.25 mg for both if eGFR
<30 or in the elderly)
• In addition, prescribe morphine 2.5 mg SC/IV + midazolam 2.5 mg SC/IV p.r.n. 4
hourly (1.25 mg for both if eGFR<30 or in the elderly)
Monitor patients receiving opioids for undesirable effects, particularly nausea and
vomiting, and constipation. Depending on individual circumstances, prescribe a regular
or p.r.n anti-emetic and a regular laxative.
Anxiety Mild • Relaxation techniques and breathing exercises
Moderate/severe • Midazolam 2.5 mg SC/IV p.r.n. (1.25 mg for both if eGFR <30 or in the elderly)
If needed regularly, consider a CSCI/IV infusion (starting dose midazolam 10 mg per
24 h; reduce to 5 mg if eGFR<30 or elderly).
Cough If continuous infusion is available
• Morphine 10 mg CSCI/IV over 24 h (5 mg CSCI/IV if eGFR <30 or elderly)
If continuous infusion is not available
• Morphine 2.5 mg SC/IV 4 hourly (1.25 mg for both if eGFR <30 or in the elderly)
Monitor patients receiving opioids for undesirable effects, particularly nausea and
vomiting, and constipation. Depending on individual circumstances, prescribe a regular
or p.r.n. anti-emetic and a regular laxative.
Fever • Paracetamol 1 g QDS PO/IV (avoid NSAIDs unless end of life)
Delirium Mild confusion • Orientation to time and place
Delirium with
distress
• Orientation to time and place, if ineffective haloperidol 1–10 mg SC/IV in 1–3 divided
doses over 24 h; maximum 10 mg per day (halve all doses in elderly; maximum 5 mg
per day)
Delirium/agitation at
end of life
• Stat dose levomepromazine 25 mg SC/IV or midazolam 5 mg (reduce to
levomepromazine 12.5 mg and midazolam 2.5 mg if eGFR <30 or elderly)
If needed regularly, consider CSCI/IV infusion (either levomepromazine 50 mg or
midazolam 15 mg per 24 h; reduce to levomepromazine 25 mg or midazolam 7.5 mg (if
eGFR <20 or elderly).
Note: may need to titrate rapidly if ongoing agitation. When on both opioid and sedative:
titrate the sedative up for terminal delirium NOT the opioid.
Communication Patients • “I understand that this is an emotional time, anyone would be scared/anxious … it is
normal to be worried and scared.”
• “We do not think recovery from this illness is possible and [you/they] may die over the
next [few hours / days / short weeks].”
• “I am very sorry that you cannot have your loved ones around you, but as you can see,
you are here with us, you are not alone, we will stay with you.”
Family • “What concerns you the most?” “It’s understandable you feel this way / This must be
really hard for you / It is upsetting.” “Who is around to support you?” “Is there
something we can do to help?”
• “We are concerned about the condition of your [relative] and think that they are ‘sick
enough to die’.”
CSCI: continuous subcutaneous infusion; SC: subcutaneous; IV: intravenous; PO: per oral; BD: twice daily; GFR: glomerular filtration rate; NSAID:
non-steroidal anti-inflammatory drugs. Further information/resources available at: https://www.vitaltalk.org/guides/covid-19-communication-
skills/, SIGN delirium guidance https://www.sign.ac.uk/sign-157-delirium
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Psychological support
Families of patients with COVID-19 face a significant psychological burden that is often magnified by
family members themselves being in isolation or under financial strain. Often, more than one member of
the same family may be infected and in hospital. Visiting is likely to also be limited/prohibited. There may
FIGURE 1 Example information sheet for coronavirus disease 2019 (COVID-19) patients admitted to hospital.
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also be guilt over possibly transmitting the infection to their loved one. The quality of the dying
experience and lack of preparation for the death are both predictors of complicated grief. Health
professionals should communicate with families regularly and where possible facilitate communication
FIGURE 2 Example information sheet for families/friends of coronavirus disease 2019 (COVID-19) patients admitted to hospital.
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between patients and their families utilising virtual technology [25]. Information leaflets should be
provided for both patients and family members. If family members are unable to visit, leaflets should be
emailed where possible. Figures 1 and 2 provide example leaflets that can be used and are also provided as
supplementary files in downloadable and editable document format. Translations are available at https://
www.europeanlung.org/en/news-and-events/news/covid-19-factsheets
Information needs and parallel planning
In patients with severe disease, there is a need for parallel planning: hoping for the best but preparing for
the worst. Therefore, there is an urgent need for early and honest discussions at the time of
hospitalisation/diagnosis of COVID-19 for those with a high risk of severe illness and death. Health
professionals should focus on advance care planning with open and honest conversations as to what is
important to the individual, to inform treatment escalation planning, including resuscitation status, should
they deteriorate.
Health professionals should acknowledge the distress of this complex and unique situation, and be
compassionate, respectful and empathic. We must explain that active resuscitative care and symptom
management do not need to be mutually exclusive, where resources allow. The focus of care should be
iterative, adapting to worsening clinical status or patient expressed altered goals of care. Importantly,
healthcare professionals need to be proactive in the provision of information and ensure that if there is
a significant possibility that the patient will die, that this is addressed with both the patient and family
(table 1).
Spiritual care
The importance of spirituality in coping with uncertainty, severe disease and at the end of life is
recognised [26]. Spiritual wellbeing offers some protection against end of life despair in those for whom
death is imminent [26]. Hospital chaplains provide spiritual care that helps patients facing serious illness
better cope with their symptoms and prognosis. Most hospitals around the world will have chaplains/
representatives from all faiths in the chaplaincy office. The family of the patient or the dying patient may
want to see speak to someone about their impending death. Chaplain interventions, whether or not
religious, focused on comforting the patient and improving his or her well-being in the context of both his
or her spiritual pain and critical illness should be explored with all patients and family [27]. It is
important that the spiritual care needs of those who are not represented by chaplaincy available or who
are not religious, should also be addressed.
Conclusion
COVID-19 patients with severe disease/at the end of life have an equal right to care. Receiving adequate
symptom control is a basic human right and we have a fundamental duty to relieve suffering and provide
the best care with the available resources regardless of the chances of survival.
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